

Human VEGF-Bevacizumab Purified No Carrier Protein

Biosimilar Recombinant Human Monoclonal Antibody

Product Information

Product No.: LT400
Clone: A4.6.1
RRID: AB_2893954
Isotype: Human IgG1κ
Storage: Sterile 2 to 8°C

Product Description

Specificity:

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only.

Antigen Distribution:

VEGF is widely expressed in the thyroid, prostate, and various other tissues.

Background:

Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.¹ Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.

Known Reactivity Species:

Human

Expression Host:

HEK-293 Cells

Format:

Purified No Carrier Protein

Immunogen:

Recombinant human VEGF.

Formulation

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Purity

≥95% by SDS Page, ≥95% monomer by analytical SEC

Endotoxin

< 1.0 EU/mg as determined by the LAL method

Product Datasheet

www.leinco.com

Storage and Stability

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at $\leq -70^{\circ}\text{C}$.

Avoid Repeated Freeze Thaw Cycles.

Product Preparation

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco's recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Applications

Applications and Recommended Usage (Quality Tested By Leinco):

FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is $\leq 0.25\text{ }\mu\text{g}$ per 10^6 cells in a volume of $100\text{ }\mu\text{l}$. Titration of the reagent is recommended for optimal performance for each application.

WB

ELISA

Other Applications Reported in Literature:

B

N

IP

Country of Origin

USA

References

1. Pazdur, R. et al. (2018) Clin Cancer Res. 24(18):4365-70.